Neuro-Oncology Symposium 2022: Enabling Technologies for Brain Tumor Care - May 21, 2022

According to the National Brain Tumor Society, an estimated 700,000 people in the United States are living with a primary brain tumor, and approximately 88,970 more will be diagnosed in 2022. Treatment and surgical options in brain tumor care continue to evolve as new technologies emerge as well as new ways of thinking which lead to shifts in how brain tumor care is provided. This course will review progress, updates, and breakthroughs that enable the technologies available in treating brain tumors.
When May 21, 2022
from 07:30 AM to 04:15 PM
Where UofL University Club & Alumni Center Ballroom, 200 E Brandeis Ave., Louisville, KY 40208 + Virtual Option Available via Zoom
Contact Name
Contact Phone 502-588-2578
Add event to calendarvCal


Target Audience

General practitioners, surgeons, ENTs, nurses, nurse practitioners, radiologists, health techs, oncologists, radiation oncologists, physical therapists, rehabilitation specialists, physiatrists.

Saturday, May 21, 2022

7:30 am
Registration & Breakfast
Open Virtual Lobby for Teleconference Audience to Join

7:50 am
Drs. Andaouz, Mistry & Williams

8:00 am – 8:30 am
Teleconference in Clinical Assessment and Nursing
Allie Schaber, APRN

8:30 am – 8:45 am

8:45 am – 9:35 am
Molecular Technologies for Diagnosis
Dr. Akshitkumar Mistry

9:35 am – 9:45 am

9:45 am – 10:00 am

10:00 am – 10:30 am
Technologies & Interventions in Rehabilitation Medicine
Dr. Megan Nelson

10:30 am – 10:45 am

10:45 am – 12:00 pm

12:00 pm – 12:50 pm
Minimally Invasive Surgical Technologies
Dr. Brian Williams

12:50 pm – 1:00 pm

1:00 pm – 1:50 pm
KEYNOTE: Advancement in Vestibular Schwannomas Care
Dr. Michael Link

1:50 pm – 2:00 pm

2:00 pm – 2:10 pm

2:10 pm – 3:00 pm
Intraoperative MRI in Brain Tumor Resection
 Dr. Jesse Savage

3:00 pm – 3:10 pm

3:10 pm – 4:00 pm
Intraoperative Radiotherapy for Brain Tumors
Dr. Chris Cifarelli 

4:00 pm – 4:10 pm

4:15 pm

Course Directors
 Norberto Andaluz, MD
Specialty Brain Tumor Care
Department of Neurosurgery
University of Cincinnati
Cincinnati, Ohio

 Akshitkumar Mistry, MD
Assistant Professor
Specialty: Brain Tumor Program
Department of Neurosurgery
University of Louisville
Louisville, Kentucky

 Brian Williams, MD
Director of Brain Tumor Program
Neurosurgery Residency Program Co-Director
Assistant Professor Neurosurgery
Department of Neurological Surgery
University of Louisville School of Medicine

Participating Faculty
Chris Cifarelli, MD, PhD    
Associate Professor
Department of Neurosurgery
Western Virginia University
Morgantown, West Virginia

Michael J. Link, MD
Department of Neurosurgery
Mayo Clinic
Rochester, Minnesota

Megan Nelson, MD
Associate Professor
Specialty: Cancer Rehabilitation
Department of Neurosurgery
Division of Physical Medicine & Rehabilitation
University of Louisville
Louisville, Kentucky

Jesse Savage, MD, PhD    
Associate Professor
Department of Neurosurgery
Indiana University
Indianapolis, Indiana

Alexandra Schaber, APRN
Nurse Practitioner
UofL Physicians Restorative Neuroscience
Specialty: Brain Tumor Program
University of Louisville
Louisville, Kentucky

Learning Objectives

As a result of participating in this activity, participants should be able to:

1. Discuss the biology and indicators of different brain tumors to build knowledge on diagnosis ability.
2. Describe the treatment options currently in use both locally and nationally in the treatment of brain tumors.
3. Identify ongoing rehabilitation options and best practices for patients.
4. Identify and discuss trends and future treatment options for brain tumors currently being researched.

Continuing Education Credit
 Physician Credit
- The University of Louisville Continuing Medical Education office designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse - This program has been approved by the Kentucky Board of Nursing for 8.4 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1277. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content. Completion criteria to obtain CE's: Attend entire session and complete the evaluation.

Accreditation Statement
 The University of Louisville School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Special Services

All individuals are encouraged to participate. To request disability arrangements, please contact the Tony Piedmonte at least 7 days prior to the date of this program. Continuing Medical Education and Professional Development fully complies with the legal requirements of the ADA and the rules and regulations thereof.


for a copy of the course Flyer

Registration Fees:
There is no fee to attend this event. Advance registration is required to allow for event planning.

In-person Conference
CLICK HERE to Register for the Live In-person Conference
Contact to confirm you’re meal option by May 11th

Live Webinar

CLICK HERE to Register for the Webinar version of this Conference

An email will be sent to all registrants 1 week prior and again 2 days prior with instructions for webinar sign-in.

We thank our supporting and exhibiting companies for their participation in the "Neuro-Oncology Symposium 2022: Enabling Technologies for Brain Tumor Care" conference. A final listing of supporters and exhibitors will be available at the meeting.

Accreditation Disclosure
As a provider accredited by the ACCME, the Office of CME&PD, School of Medicine, University of Louisville, must ensure balance, independence, objectivity, and scientific rigor in all its accredited educational activities. All Planners, faculty, reviewers, and other persons that affected the content of this CME activity were required to submit a financial disclosure form from which relevant conflicts of interest were determined. If any relevant financial relationship(s) with ineligible companies were disclosed, the materials each of them prepared for this program (or influenced) were peer-reviewed and determined to be without ineligible company bias, were considered fair and balanced in terms of therapeutic options, and presented evidence-based content. All relevant financial relationships with ineligible organizations have been mitigated prior to this activity.